Delphine Borchiellini

7.7k total citations · 1 hit paper
89 papers, 1.8k citations indexed

About

Delphine Borchiellini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Delphine Borchiellini has authored 89 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Delphine Borchiellini's work include Renal cell carcinoma treatment (44 papers), Cancer Immunotherapy and Biomarkers (42 papers) and Renal and related cancers (17 papers). Delphine Borchiellini is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Cancer Immunotherapy and Biomarkers (42 papers) and Renal and related cancers (17 papers). Delphine Borchiellini collaborates with scholars based in France, United States and Canada. Delphine Borchiellini's co-authors include Elizabeth R. Plimack, Bohuslav Melichar, Rustem Gafanov, Dmitry Nosov, Ihor Vynnychenko, Sérgio Jobim Azevedo, Denis Soulières, Frédéric Pouliot, Brian I. Rini and V.P. Stus and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Delphine Borchiellini

86 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Delphine Borchiellini France	22	1.2k	986	639	458	300	89	1.8k
Ben L. Sanford United States	19	1.1k 1.0×	876 0.9×	771 1.2×	487 1.1×	312 1.0×	47	2.5k
Sérgio Jobim Azevedo Brazil	19	946 0.8×	910 0.9×	436 0.7×	450 1.0×	340 1.1×	50	1.6k
Guillermo de Velasco Spain	27	1.7k 1.5×	1.3k 1.3×	910 1.4×	621 1.4×	400 1.3×	113	2.6k
Daniel Yick Chin Heng Canada	23	1.3k 1.1×	895 0.9×	726 1.1×	563 1.2×	597 2.0×	89	2.1k
Melissa Bersanelli Italy	19	796 0.7×	821 0.8×	479 0.7×	295 0.6×	192 0.6×	102	1.4k
Aly‐Khan A. Lalani Canada	19	837 0.7×	695 0.7×	467 0.7×	367 0.8×	248 0.8×	88	1.3k
Ulrika Harmenberg Sweden	23	1.0k 0.9×	736 0.7×	693 1.1×	375 0.8×	208 0.7×	57	1.7k
Philippe Barthélémy France	20	752 0.7×	765 0.8×	481 0.8×	276 0.6×	599 2.0×	123	1.6k
Jessica Menis Italy	21	1.1k 1.0×	1.2k 1.2×	381 0.6×	363 0.8×	145 0.5×	76	1.9k
Jacob J. Adashek United States	24	506 0.4×	816 0.8×	338 0.5×	416 0.9×	195 0.7×	106	1.5k

Countries citing papers authored by Delphine Borchiellini

Since Specialization

Citations

This map shows the geographic impact of Delphine Borchiellini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delphine Borchiellini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delphine Borchiellini more than expected).

Fields of papers citing papers by Delphine Borchiellini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delphine Borchiellini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delphine Borchiellini. The network helps show where Delphine Borchiellini may publish in the future.

Co-authorship network of co-authors of Delphine Borchiellini

This figure shows the co-authorship network connecting the top 25 collaborators of Delphine Borchiellini. A scholar is included among the top collaborators of Delphine Borchiellini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delphine Borchiellini. Delphine Borchiellini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.

Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations

Montemagno, Christopher, Jérôme Durivault, Maeva Dufies, et al.. (2023). A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma. Molecular Oncology. 17(7). 1379–1401. 5 indexed citations

Ferrero, Jean-Marc, Hakim Mahammedi, Gwénaëlle Gravis, et al.. (2023). Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer. Pharmaceutics. 15(2). 651–651. 3 indexed citations

Colomba, Émeline, Luca Campedel, Clément Dumont, et al.. (2022). Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers. 14(7). 1678–1678. 7 indexed citations

Borchiellini, Delphine, Aline Guillot, Jean-Baptiste Paoli, et al.. (2021). TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 19(6). 501–509. 34 indexed citations

Gérard, Alexandre O., Marine Andreani, Nadège Parassol, et al.. (2021). Immune checkpoint inhibitors-induced nephropathy: a French national survey. Cancer Immunology Immunotherapy. 70(11). 3357–3364. 11 indexed citations

Barrière, Jérôme, et al.. (2021). Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey. Annals of Oncology. 32(5). 673–674. 67 indexed citations

Derosa, Lisa, Cécile Dalban, Émeline Colomba, et al.. (2021). 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N). Annals of Oncology. 32. S710–S710. 5 indexed citations

10.

Kinj, Rémy, J. Doyen, Jean‐Michel Hannoun‐Lévi, et al.. (2020). Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse. Clinical Oncology. 33(1). e15–e21. 4 indexed citations

11.

Thibault, Constance, Damien Pouessel, Aude Fléchon, et al.. (2020). 1059P NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma. Annals of Oncology. 31. S723–S723. 4 indexed citations

12.

Gross‐Goupil, Marine, Valérie Seegers, Benoit Beuselinck, et al.. (2020). Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. European Journal of Cancer. 136. 76–83. 20 indexed citations

13.

Barthélémy, Philippe, Clément Dumont, Brigitte Laguerre, et al.. (2020). 735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study. Annals of Oncology. 31. S574–S574. 3 indexed citations

14.

Vano, Yann, Mostefa Bennamoun, Christine Chevreau, et al.. (2020). LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology. 31. S1157–S1157. 26 indexed citations

15.

Gal, Jocelyn, Nathalie Ebran, Josiane Otto, et al.. (2019). Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Investigational New Drugs. 38(1). 160–171. 37 indexed citations

16.

Giuliano, Sandy, Maeva Dufies, Papa Diogop Ndiaye, et al.. (2019). Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. Theranostics. 9(4). 1181–1199. 24 indexed citations

17.

Borchiellini, Delphine, Benjamin Hoch, Vittoria Raimondi, et al.. (2019). Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study. Supportive Care in Cancer. 28(4). 1639–1647. 10 indexed citations

18.

Humbert, Olivier, Renaud Schiappa, M. Poudenx, et al.. (2019). 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. European Journal of Nuclear Medicine and Molecular Imaging. 47(5). 1158–1167. 61 indexed citations

19.

Loriot, Yohann, S. Supiot, Jean‐Baptiste Beauval, et al.. (2018). Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews. 70. 223–231. 17 indexed citations

20.

Pignot, G., Denis Maillet, Philippe Barthélémy, et al.. (2018). Systemic treatments for high-risk localized prostate cancer. Nature Reviews Urology. 15(8). 498–510. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact